Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE
Date Title  
Thursday, September 22, 2016 Five Prime Therapeutics to Present at the LEERINK Partners Rare Disease & Immuno-Oncology Roundtable
Tuesday, September 20, 2016 Five Prime Therapeutics Announces Key Executive Promotions
Upcoming and Recent Events > MORE
Date Title  
Thursday, September 29, 2016
11:00 AM ET
LEERINK Partners Rare Disease & Immuno-Oncology Roundtable
Supporting Materials
PDF View Presentation  2.1 MB   Add to Briefcase
Monday, September 19, 2016
Five Prime Therapeutics Rings the NASDAQ Stock Market Opening Bell
Tuesday, September 13, 2016
4:40 PM ET
Morgan Stanley Global Healthcare Conference
Supporting Materials
PDF Corporate Overview  2.1 MB   Add to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
51.84
Change (%)
-1.72
Volume
417,458

Data as of 4:00 PM ET on Thursday, September 29, 2016
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.